Small-molecule treatments to boost brain potassium (Kv) channels

Therapeutic small molecule modulation of Kv channels

['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11226392

Plant-derived small molecules that open specific brain potassium channels to help people with epilepsy, certain ataxias, hereditary spastic paraplegia, or cocaine addiction.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF CALIFORNIA-IRVINE (nih funded)
Locations1 site (IRVINE, UNITED STATES)
Trial IDNIH-11226392 on ClinicalTrials.gov

What this research studies

Researchers are working to understand how plant-derived compounds like diterpenes and hydroxybenzoic acids open neuronal Kv7 and Kv1 potassium channels and whether that can ease symptoms of epilepsy, ataxia, hereditary spastic paraplegia, or addiction. The team combines computer-based molecular modeling, targeted genetic changes to channels, electrical recordings of channel activity, and testing in mouse models. Some compounds (for example, carnosic acid) already cross the blood-brain barrier, show good safety in prior rodent and human studies, and reduced cocaine-seeking in mice. The goal is to define how these molecules work and whether they can be optimized toward future therapies for people.

Who could benefit from this research

Good fit: People with forms of epilepsy linked to Kv channel dysfunction, episodic ataxia, hereditary spastic paraplegia, or individuals seeking treatment for cocaine addiction would be the most likely future candidates.

Not a fit: Patients whose conditions are not related to Kv channel loss-of-function or who have contraindications to small-molecule therapy are unlikely to benefit from these specific approaches.

Why it matters

Potential benefit: If successful, this work could lead to new oral medicines that reduce seizures, improve coordination in ataxia, or decrease addictive behaviors by restoring Kv channel function.

How similar studies have performed: Preclinical work has shown promise: carnosic acid opens Kv7.3/5 channels and reduced cocaine-seeking in mice, and these compounds have favorable safety data, but clinical benefit in patients has not yet been proven.

Where this research is happening

IRVINE, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.